Illustration of a bone healing from damage, symbolizing rheumatoid arthritis repair.

Can Damaged Joints Really Heal? The Surprising Truth About Rheumatoid Arthritis and Bone Repair

Jordan Keane monogram
Jordan Keane in Health & Wellness November 2026 • 4 min read.

"New research reveals that bone erosion caused by rheumatoid arthritis may not be as permanent as once thought, offering hope for better long-term outcomes."


Rheumatoid arthritis (RA) has long been viewed as a relentless condition, marked by progressive joint damage and bone erosion. For many, the diagnosis conjures images of irreversible deterioration, leading to decreased mobility and chronic pain. However, emerging research is beginning to challenge this long-held belief, suggesting that the body may have a greater capacity for bone repair than previously understood.

A groundbreaking study presented at the European League Against Rheumatism (EULAR) conference sheds light on the potential for bone erosion repair in RA patients. This challenges the traditional understanding of RA as a one-way street of destruction, offering a beacon of hope for those living with the condition.

This article explores the findings of this pivotal study, examining the evidence for bone repair, the factors that influence it, and what this could mean for the future of RA treatment. We'll delve into the specifics of the research, simplifying complex data for a broad audience and highlighting the potential for a more optimistic outlook on managing RA.

AI Search Multiple angles on this topic

RA’s Joint Burden

Rheumatoid arthritis can damage joints through persistent inflammation, but its effects vary considerably among individuals. Some people develop limited structural change, while others experience progressive erosion and disability. The extent and pace of damage depend on disease activity and other factors, so general statistics should be interpreted cautiously.

Controlling Damage

Standard care generally focuses on controlling rheumatoid arthritis inflammation and preventing further joint damage. These approaches may reduce disease activity, but they do not guarantee that established bone erosions will fully repair. Treatment response and structural outcomes can differ substantially between patients.

Changing Views of Repair

Rheumatoid arthritis has historically been associated with progressive joint destruction rather than dependable bone repair. Advances in disease treatment have improved the possibility of limiting radiographic damage. Even so, the idea that damaged erosions might sometimes change or partially repair remains an area of continuing investigation.

The BARFOT Study: A Closer Look at Bone Erosion Repair

Illustration of a bone healing from damage, symbolizing rheumatoid arthritis repair.

The study, known as the BARFOT (Better Anti-Rheumatic FarmacoTherapy) study, followed 473 patients with early RA over eight years. Researchers meticulously tracked the presence and extent of bone erosions using the Sharp-van der Heijde scoring (SHS) method, a standard tool for assessing joint damage in RA. What they discovered was surprising: a significant number of patients showed signs of bone erosion repair over time.

Specifically, the study found that:

  • After one year, 17% of patients showed evidence of erosion repair.
  • This number increased to 30% after two years, 38% after five years, and 51% after eight years.
  • The number of erosions showing repair also increased over time, with 153, 260, 424, and 717 erosions repaired at 1, 2, 5, and 8 years, respectively.
AI Search Multiple angles on this topic

New Evidence on Erosion

Recent research describes rheumatoid arthritis as a chronic autoimmune disease marked by persistent synovial inflammation and progressive bone erosion. Excessive osteoclastogenesis is identified as a central process driving RA-associated bone destruction. A 2025 report also emphasizes that RA ranges from non-erosive disease to severely mutilating erosive disease, with large differences in radiographic progression even over one year. Separately, a 2026 study is investigating sweroside, a bioactive iridoid glycoside, for potential effects against RA-associated bone damage, while a review reports that RA affects approximately 1% of the global population and is linked to periarticular osteopenia, marginal erosions, and generalized osteoporosis.

Why Repair Is Uncertain

Evidence that rheumatoid arthritis bone damage can heal remains limited and should not be treated as a predictable outcome. Inflammation may continue to drive erosion, and patients can show very different rates of structural progression. Consequently, preventing additional damage remains a more established goal than reliably rebuilding already eroded bone.

Different Disease Courses

Rheumatoid arthritis does not follow one uniform structural course. The disease can be non-erosive in some people but severely erosive in others, and radiographic progression can differ substantially even within a single year. This variation makes broad comparisons between patients difficult and supports individualized assessment of joint damage.

These findings suggest that bone erosion repair is not only possible but also relatively common in RA patients, particularly in the early stages of the disease. This challenges the traditional view of RA as a condition of irreversible joint damage.

A New Dawn for Rheumatoid Arthritis Treatment?

The discovery of bone erosion repair in RA patients offers a renewed sense of optimism for those living with this chronic condition. While the study highlights the potential for repair, it also underscores the importance of early and aggressive treatment to minimize initial damage and create an environment conducive to healing. Further research is needed to fully understand the mechanisms behind bone repair and to develop targeted therapies that can promote this process. However, the BARFOT study represents a significant step forward in our understanding of RA and opens the door to a future where joint damage may not be as irreversible as once thought.

AI Search Multiple angles on this topic

A Qualified Yes

The available evidence supports a cautious answer: rheumatoid arthritis bone erosions are not necessarily permanently unchangeable, but dependable repair is not established. Persistent inflammation and osteoclast activity can continue to promote bone loss. Any apparent repair should therefore be evaluated alongside disease control, imaging findings, and the individual patient’s clinical course.

Tracking Structural Change

Future research is likely to focus on detecting small changes in erosion earlier and determining which patients might be capable of repair. More sensitive imaging and studies of bone-resorbing pathways may help clarify these differences. Investigational approaches, including work on sweroside and other disease-modifying treatments, may expand understanding, but their therapeutic value remains to be established.

Local and Systemic Bone Loss

Rheumatoid arthritis affects bone at both local and systemic levels. Periarticular cortical erosion results from excessive local bone resorption and inadequate bone formation, while systemic osteoporosis can be associated with inflammation, glucocorticoid therapy, and physical impairment. Reviews also describe periarticular osteopenia and joint erosions as localized forms of bone loss, emphasizing that bone is an active participant in inflammatory arthritis rather than merely a passive target.

Repair and Function

Bone erosion has traditionally been considered almost irreversible, although radiographic repair has occasionally been reported. A 2013 report described dramatic radiographic repair with tocilizumab in a very elderly patient, while a 2026 case report described erosion repair after treatment with a Janus kinase inhibitor in a 75-year-old man with an eight-year history of rheumatoid arthritis. Newer research is examining whether partial erosion repair measured by high-resolution peripheral quantitative CT is independently associated with functional outcomes in early rheumatoid arthritis. These reports are encouraging but represent limited evidence rather than a guarantee that repair will restore function for every patient.

Repair figures alongside their comparisons

  • 10.7% of patientsErosion repair was detected in 10.7% of patients receiving conventional DMARDs.[1]
  • 20% vs 6% of groups at 24 monthsAt 24 months, bone erosion repair was reported in 20% of the denosumab group and 6% of the placebo group.[2]
  • 19% vs 9%; 18% vs 8% of groups at 24 monthsIn the same comparison, new erosions occurred in 19% of the placebo group and 9% of the denosumab group; erosion progression occurred in 18% and 8%, respectively.[2]

What erosion changes can-and cannot-show

The reports describe erosion repair alongside reduced disease activity or controlled inflammation, consistent with inflammation being relevant to whether focal bone repair occurs. They do not establish that repair is dependable across patients or that a radiographic change restores joint function.[1] [3] [4]

A mouse model offers a possible biological explanation: resolving inflammation was associated with more mature osteoblasts at erosion sites and new bone formation. This supports a mechanism to investigate, but animal-model findings do not themselves establish the same process in people.[5]

Denosumab was also described as partly repairing erosions by reducing their width, depth, and volume. That finding concerns measured structural dimensions; it does not by itself establish recovery of cartilage or function.[5]

How treatment comparisons and imaging reports differ

A separate report described partial repair and reduced erosion depth after TNF-inhibitor treatment, while erosions in patients receiving methotrexate worsened. This is a contrast between reported treatment groups, not evidence that every patient has the same structural response.[5]

For certolizumab, the reported share with mTSS at or below 0.5 at week 52 was 82.9%, compared with 70.7% on placebo; mean mTSS change was 0.36 versus 1.58. These are structural-damage measures, not direct measures of erosion repair.[6]

The denosumab comparison had fewer participants with erosions in the targeted metacarpal heads than planned: 8 patients (38.1%) in the combination group and 13 (59.1%) in the csDMARD-only group. This describes the sample’s erosion distribution and does not alone establish how broadly the results apply.[2]

What remains unresolved about measuring repair

  • How much of an apparent change in joint-space narrowing represents biological cartilage repair, rather than differences in joint alignment between radiographs? The cited report notes that hand and wrist positioning was not fixed with molds and that the apparent repair could have been coincidental.[7]
  • Do reductions in erosion width, depth, or volume correspond to meaningful changes in symptoms or function? The cited denosumab finding describes structural dimensions, not those outcomes.[5]

Sources

  1. Bone erosions in rheumatoid arthritis can be repaired through reduction in disease activity with conventional disease-modifying antirheumatic drugs (pmc.ncbi.nlm.nih.gov)
  2. Inhibition of bone erosion, determined by high-resolution peripheral quantitative computed tomography (HR-pQCT), in rheumatoid arthritis patients receiving a conventional synthetic disease-modifying a (pmc.ncbi.nlm.nih.gov)
  3. Repair of joint erosions in rheumatoid arthritis: prevalence and patient characteristics in a large inception cohort. (pubmed.ncbi.nlm.nih.gov)
  4. Osteoblast role in the pathogenesis of rheumatoid arthritis (pmc.ncbi.nlm.nih.gov)
  5. Bone erosions in rheumatoid arthritis: recent developments in pathogenesis and therapeutic implications (pmc.ncbi.nlm.nih.gov)
  6. Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study (pmc.ncbi.nlm.nih.gov)
  7. Repair of joint damage in patients with rheumatoid arthritis does not relate to previous suppression of inflammation: a subanalysis after 8 years treat-to-target in the BeSt-trial (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What is Rheumatoid Arthritis (RA), and how is it typically understood in terms of joint and bone damage?

Rheumatoid Arthritis (RA) is a chronic autoimmune disease that primarily affects the joints. Traditionally, RA has been viewed as a condition leading to progressive joint damage and bone erosion, often considered irreversible. This understanding has shaped treatment approaches and the expectations of those living with RA, often leading to concerns about decreased mobility and chronic pain. However, recent research challenges this view, suggesting a greater potential for bone repair than previously thought.

2

What specific study provides evidence of bone erosion repair in Rheumatoid Arthritis, and what were its key findings?

The BARFOT (Better Anti-Rheumatic FarmacoTherapy) study, presented at the European League Against Rheumatism (EULAR) conference, provides evidence of bone erosion repair in RA patients. This study followed 473 patients with early RA over eight years using the Sharp-van der Heijde scoring (SHS) method. The study found that a significant number of patients showed signs of bone erosion repair over time: 17% after one year, 30% after two years, 38% after five years, and 51% after eight years. Additionally, the number of repaired erosions increased over time, indicating that bone repair is not only possible but also relatively common in RA patients.

3

What is the Sharp-van der Heijde scoring (SHS) method, and why is it significant in the context of Rheumatoid Arthritis research?

The Sharp-van der Heijde scoring (SHS) method is a standard tool used to assess joint damage in Rheumatoid Arthritis (RA). It allows researchers to meticulously track the presence and extent of bone erosions in RA patients over time. The significance of SHS in the BARFOT study is that it provided a quantifiable way to measure bone erosion and, crucially, to identify and track instances of repair. This method was instrumental in demonstrating that bone erosion repair is possible in RA patients, challenging the long-held belief of irreversible damage.

4

How does the discovery of bone erosion repair in RA change the outlook for patients and the approach to treatment?

The discovery of bone erosion repair offers a renewed sense of optimism for individuals living with RA. It suggests that joint damage may not be as irreversible as previously thought. This finding emphasizes the importance of early and aggressive treatment strategies to minimize initial damage and foster an environment conducive to healing. The possibility of bone repair opens the door to developing targeted therapies that can promote this process, potentially leading to better long-term outcomes for patients with RA.

5

What further research is needed to build upon the findings of the BARFOT study, and what are the implications for the future of Rheumatoid Arthritis treatment?

While the BARFOT study is a significant step forward, further research is needed to fully understand the mechanisms behind bone repair in RA. This includes identifying the specific factors that promote bone repair and developing targeted therapies to enhance this process. This could involve investigating the role of different medications, lifestyle interventions, and innovative treatment approaches. The implications for the future of RA treatment are substantial, potentially leading to more effective treatments that not only manage symptoms but also promote joint healing, ultimately improving the quality of life for individuals living with RA.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.